Teladoc price target lowered to $25 from $30 at RBC Capital

RBC Capital analyst Sean Dodge lowered the firm’s price target on Teladoc to $25 from $30 but keeps an Outperform rating on the shares. The company’s Q4 update was mixed with EBITDA that was better than expected but a longer-range revenue growth outlook of low-mid single digts that will likely be viewed as “disappointing” against the 7% growth rate implied in consensus, the analyst tells investors in a research note. The firm is rolling forward its multiple with assumed 11-times expected 2025 EBITDA estimate vs. 15-times expected 2024 EBITDA view prior, RBC added.